Welcome a new era of therapeutic development in which natural compounds can be leveraged to accelerate the delivery of breakthrough medical solutions.
Our mission is to improve patient outcomes by advancing therapy for critical illness.
Andira is a privately held health science firm, leveraging natural compounds to accelerate the delivery of urgently-needed solutions for antibiotic-resistant infections and metastatic cancer.
Andira is home to:
Novel Pharmacotherapeutic Platform
Applying proven innovation to generate a consistent stream of technologies that address highly prevalent medical conditions
Therapeutic and Medical Device Products
Following established regulatory pathways to achieve product approvals
An Industry-Leading Team
A proven track record of pharmaceutical commercialization success through execution of viable scientific, clinical and regulatory strategies
Our novel, Matrix3 triple synergy formula provides faster onset and improved efficacy against drug-resistant bacteria including MRSA and Pseudomonas.
Hospital Acquired Infections
Our Hospital Infections program is advancing an injectable product for Drug-Resistant Enterococcus (“VRE”) – a life-threatening hospital-acquired infection.
Andira uses the most translational research techniques available to optimize treatments to address Metastatic Breast Cancer.
COMPANY NEWS AND EVENTS
Life Sciences Review has awarded Andira Pharmaceuticals the Top Therapeutic & Medical Device Products Provider 2023, and feature Andira in the August 17, 2023 issue with CEO, Dana Lambert,
Andira Pharmaceuticals’ US Patent Allowed in Breakthrough Therapeutic Treatment to Address Deadly Antibiotic-Resistant Infections
Opportunity to invest in Canadian health science firm pioneering a new generation of patented therapeutics for drug-resistant infection is now open globally to eligible investors. SAN FRANCISCO, AUGUST 2023